Development of PSMA-Targeted Liposomal Zinc for Prostate Cancer Therapy
Nanomaterials · 08.06.2026 · 16 (12) · 705
DOI: 10.3390/nano16120705 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nanomaterials, online erschienen am 08.06.2026. Verfasst von Sujan Kumar Mondal und 3 weiteren Autor:innen. Beteiligte Einrichtung: Precision Health Program, Michigan State University, 766 Service Road, East Lansing, MI 48824, USA. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIH, Quantitative Bio-Element Analysis and Mapping (QBEAM) Center at Michigan State University.
Abstract (Originalsprache)
Normal prostate epithelial cells accumulate high intracellular zinc levels that maintain optimum mitochondrial metabolism and proliferation. Prostate cancer cells lose this zinc-accumulating capacity, enabling metabolic reprogramming that supports tumor progression. Restoring intracellular zinc selectively in prostate tumors represents a promising therapeutic strategy; however, systemic zinc administration is limited by the inability of prostate cancer cells to take up free zinc resulting from ZIP1 transporter downregulation. To overcome this challenge, we developed a formulation of prostate-specific membrane antigen (PSMA)-targeted, zinc-loaded liposomes (Zn-TL) to enable tumor-selective intracellular zinc delivery. Zn-TL was prepared with uniform nanoscale size, low polydispersity, and negative surface charge. The formulation showed minimal zinc leakage during storage and sustained retention in vitro. In prostate cancer cells, Zn-TL demonstrated receptor-mediated uptake, resulting in increased cytotoxicity and apoptosis. In vivo, we performed proof-of-principle studies showing prolonged circulation and tumor accumulation of Zn-TL in mice bearing PSMA-positive tumors. While tumor growth was delayed during early and intermediate stages of tumor development, this effect diminished at later stages. The stage-dependent efficacy suggests that Zn-TL may be most effective when used earlier in disease progression. These results also suggest that Zn-TL represents a promising platform for metabolic intervention and may benefit from combination strategies to enhance efficacy in advanced disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Precision Health Program, Michigan State University, 766 Service Road, East Lansing, MI 48824, USA.
- Department of Radiology, College of Human Medicine, Michigan State University, 846 Service Road, East Lansing, MI 48824, USA.
- Department of Medicine, University of Virginia, Davis Wing, Hospital Drive, Suite 5357, Charlottesville, VA 22904, USA.
ORCID-Profile: Sujan Kumar Mondal, Alexander L Klibanov, Anna Moore
Förderung
- NIH HHS
- NIH
- Quantitative Bio-Element Analysis and Mapping (QBEAM) Center at Michigan State University
Zitieren
APA
Mondal, S. K., Kenyon, E., Klibanov, A. L., & Moore, A. (2026). Development of PSMA-Targeted Liposomal Zinc for Prostate Cancer Therapy. Nanomaterials, 16(12), 705. https://doi.org/10.3390/nano16120705
Vancouver
Mondal SK, Kenyon E, Klibanov AL, Moore A. Development of PSMA-Targeted Liposomal Zinc for Prostate Cancer Therapy. Nanomaterials. 2026;16(12):705. doi:10.3390/nano16120705
BibTeX
@article{Mondal2026,
author = {Mondal, Sujan Kumar and Kenyon, Elizabeth and Klibanov, Alexander L and Moore, Anna},
title = {Development of PSMA-Targeted Liposomal Zinc for Prostate Cancer Therapy},
journal = {Nanomaterials},
year = {2026},
volume = {16},
number = {12},
pages = {705},
doi = {10.3390/nano16120705}
}
EUVIMED